Overview
Cysticercosis is a parasitic tissue infection caused by the larval cysts (cysticerci) of the pork tapeworm, Taenia solium. It is not a genetic disease but rather an acquired infectious condition. Humans become infected by ingesting T. solium eggs, typically through fecal-oral transmission from contaminated food, water, or contact with an infected individual who harbors the adult tapeworm. Once ingested, the larvae can migrate to various tissues throughout the body, forming cysts most commonly in the brain (neurocysticercosis), skeletal muscles, subcutaneous tissues, and eyes (ocular cysticercosis). Neurocysticercosis (NCC) is the most clinically significant form and is the leading cause of acquired epilepsy in endemic regions worldwide. Key symptoms depend on the location, number, and stage of the cysts and include seizures, chronic headaches, increased intracranial pressure (hydrocephalus), cognitive decline, focal neurological deficits, and meningitis. Ocular cysticercosis can cause visual disturbances, eye pain, and vision loss. Subcutaneous and muscular cysticercosis may present as painless nodules under the skin. Cysticercosis is endemic in many low- and middle-income countries in Latin America, sub-Saharan Africa, and Asia, where sanitation infrastructure is limited and pigs are raised in close contact with humans. Treatment depends on the form and severity of disease. Antiparasitic medications such as albendazole and praziquantel are used to kill viable cysts, often in combination with corticosteroids (such as dexamethasone) to manage the inflammatory response triggered by cyst degeneration. Antiepileptic drugs are used to control seizures. Surgical intervention may be necessary for cases involving hydrocephalus, large cysts, or intraventricular or spinal cysts. Prevention strategies focus on improved sanitation, meat inspection, health education, and mass treatment programs in endemic areas.
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
4 eventsCephas Health Research Initiative Inc, Ibadan, Nigeria — NA
Universidad Peruana Cayetano Heredia — PHASE2, PHASE3
R-Evolution Worldwide S.r.l. Impresa Sociale — PHASE4
National Institute of Allergy and Infectious Diseases (NIAID)
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableAlbenza
Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Cysticercosis.
Community
No community posts yet. Be the first to share your experience with Cysticercosis.
Start the conversation →Latest news about Cysticercosis
Disease timeline:
New recruiting trial: Natural History of Treated Neurocysticercosis and Long-Term Outcomes
A new clinical trial is recruiting patients for Cysticercosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Cysticercosis
What is Cysticercosis?
Cysticercosis is a parasitic tissue infection caused by the larval cysts (cysticerci) of the pork tapeworm, Taenia solium. It is not a genetic disease but rather an acquired infectious condition. Humans become infected by ingesting T. solium eggs, typically through fecal-oral transmission from contaminated food, water, or contact with an infected individual who harbors the adult tapeworm. Once ingested, the larvae can migrate to various tissues throughout the body, forming cysts most commonly in the brain (neurocysticercosis), skeletal muscles, subcutaneous tissues, and eyes (ocular cysticerco
Are there clinical trials for Cysticercosis?
Yes — 1 recruiting clinical trial is currently listed for Cysticercosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Cysticercosis?
25 specialists and care centers treating Cysticercosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Cysticercosis?
1 patient support program are currently tracked on UniteRare for Cysticercosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.